AMS IS THE INDUSTRY LEADER IN STRATEGIC INTELLIGENCE SOFTWARE FOR COMBATTING EMERGING HIGH-COST CLAIM ISSUES
What We Do:
AMS provides tech-enabled healthcare solutions delivering crucial insight into catastrophic diagnoses, specialty pharmaceutical, and implant price transparency by means of clinically vetted, predictive financial analytics with near real-time data.
Who We Serve:
AMS serves multiple stakeholders in the medical claims payment chain, including commercial and governmental payers, Stop Loss and Reinsurance Carriers, MGUs, Medical Management Firms, Health Plans, TPAs, HMOs, Taft-Hartley Plans, workers compensation, and auto medical carriers.
WHO IS USING THE PREDICT SUITE
THE PREDICT SUITE
AMS’ Web-based directories that allow
clients to predict, evaluate and manage high dollar healthcare claims.
PREDICT
Predict costs and clinical treatments for high dollar diagnoses with an on demand decision support solution delivering in-depth clinical information, empirical insight and key financial analytics.
EVALUATE
Evaluate cost data, FDA approved indications, notable off-label usage, adult/pediatric dosing regimens, manufacturer rebates, specialty drug coding and price trends.
MANAGE
Manage highly inflated implant claims by leveraging detailed clinical and financial metrics with the only online, fully- transparent implant cost directory in the industry.
PREDICT SUITE MEMBERSHIP HAS ITS BENEFITS
10+M
Dollars Saved Annually
We have saved tens of millions of dollars for our clients and members
99%
Members
Retained
We have retained 99% of our members
750+
Sub Specialty
Physicians
750+ specialty physicians in our peer review panel
100s
Weekly Hours
Saved
We have saved our clients and members 100s of weekly hours in research and underwriting
AMS Blog
-
Hospitals Prepare To Launch Their Own Drug Company To Fight High Prices and Shortages
September 6, 2018
Sometimes IV bags are hard for hospitals to come by. Other times it’s injectable folic acid to treat anemias. Right now the tissue-numbing agent lidocaine is in short supply. Shortages of commonplace generic drugshave plagued hospitals in recent years. And with short supplies and fewer suppliers for key drugs, there have been price increases. Hospital… Read More » -
Study finds multiple sclerosis drug slows brain shrinkage
August 30, 2018
An NIH-funded clinical trial suggested that the anti-inflammatory drug ibudilast may slow brain shrinkage caused by progressive MS. Robert J. Fox, M.D., Cleveland Clinic, OH. Results from a clinical trial of more than 250 participants with progressive multiple sclerosis(MS) revealed that ibudilast was better than a placebo in slowing down brain shrinkage. The study… Read More »